Dulaglutide
Dulaglutide (Trulicity) is a once-weekly GLP-1 receptor agonist with proven cardiovascular benefits and a user-friendly auto-injector. It offers moderate efficacy with strong adherence due to its simple delivery system.
Evidence Summary
REWIND (Lancet, 2019; n=9,901; median 5.4 years) showed a 12% reduction in major adverse cardiovascular events (HR 0.88, 95% CI 0.79-0.99; p=0.026), notable for including a primary-prevention population (31% without established cardiovascular disease). Exploratory REWIND analyses also reported a 15% reduction in a composite kidney outcome (HR 0.85, 95% CI 0.77-0.93; p=0.0004) — driven by a 23% reduction in new macroalbuminuria (HR 0.77) — and, after adjustment for baseline scores, a 14% reduction in substantive cognitive impairment (HR 0.86, 95% CI 0.79-0.95; p=0.0018). In the head-to-head SURPASS-CVOT trial (JAMA Cardiology, 2026; n=13,165; median 46.9 months), dulaglutide 1.5 mg served as the active comparator: tirzepatide reduced a composite cardiorenal endpoint by a further 16% versus dulaglutide (HR 0.84, 95% CI 0.79-0.90; p<0.001). Dulaglutide remains a well-tolerated, cardiovascular-outcomes-proven GLP-1 option, with more potent agents now available for patients prioritizing weight loss. These are summaries of published research, not treatment claims.
Evidence Scale
Mechanism of Action
GLP-1 receptor agonist fused to a modified IgG4 Fc fragment, extending half-life to ~5 days. Enhances glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, and promotes satiety through central nervous system GLP-1 receptor activation.
Who Is This For?
Type 2 diabetes with cardiovascular risk. Patients prioritizing device simplicity. Primary cardiovascular prevention in diabetic patients.
Protocol & Dosing
Dose
Start 0.75mg weekly for 4 weeks, then increase to 1.5mg weekly. Maximum dose: 4.5mg weekly.
Frequency
Weekly injection
Duration
Ongoing / Long-term
Protocol Summary
Weekly subcutaneous injection via pre-filled auto-injector. REWIND trial uniquely included primary CV prevention population. Moderate efficacy but highest ease-of-use rating.
Interactions & Precautions
Contraindications
- Medullary thyroid carcinoma history
- MEN2
- Severe GI disease
- Pancreatitis history
Potential Risks
- •Thyroid tumor risk
- •Pancreatitis
- •Gallbladder events
Potential Side Effects
Practitioner Notes
Clinical annotations from Dr. Goel
Good option for patients who value simple injection technique and a long safety record. Less weight loss than semaglutide or tirzepatide — manage expectations. Strong choice for primary cardiovascular prevention in diabetes based on REWIND, with exploratory signals for kidney and cognitive protection. The 2026 SURPASS-CVOT head-to-head used dulaglutide 1.5 mg as the active comparator and found tirzepatide superior on the composite cardiorenal endpoint, so consider upgrading when greater metabolic potency is the goal. Educational information, not medical advice.
Dr. Sanjeev Goel
Chief Medical Officer, Peak Human
Latest Evidence
2024-2026: where dulaglutide stands among the GLP-1s
Dulaglutide (Trulicity) is one of the most thoroughly studied once-weekly GLP-1 receptor agonists. Its landmark REWIND trial (Lancet, 2019; 9,901 participants, median 5.4 years) remains distinctive for enrolling a large primary-prevention group - 31% had no established cardiovascular disease - and still showed a 12% reduction in major adverse cardiovascular events (HR 0.88, 95% CI 0.79-0.99; p=0.026). Exploratory REWIND analyses pointed to protection beyond the heart: a 15% lower composite kidney outcome (HR 0.85, 95% CI 0.77-0.93), led by a 23% drop in new macroalbuminuria, and - after adjustment for baseline scores - a 14% reduction in substantive cognitive impairment (HR 0.86, 95% CI 0.79-0.95; p=0.0018).
The newest head-to-head data reframe where dulaglutide sits in 2026. In SURPASS-CVOT (JAMA Cardiology, 2026; 13,165 patients with type 2 diabetes and established cardiovascular disease, median 46.9 months), dulaglutide 1.5 mg was the active comparator against tirzepatide. Tirzepatide reduced a six-component composite cardiorenal endpoint by a further 16% versus dulaglutide (HR 0.84, 95% CI 0.79-0.90; p<0.001), including lower all-cause mortality (HR 0.84) and fewer kidney events (HR 0.79). The practical read: dulaglutide delivers robust, well-tolerated, outcomes-proven benefit, while more potent incretins now offer incremental cardiorenal and weight advantages for suitable patients.
Dulaglutide is FDA- and Health Canada-approved for type 2 diabetes; it is not approved for cognitive or kidney indications, and the cognitive and renal findings above are exploratory. These are summaries of published research, not treatment claims. Educational information, not medical advice - discuss any GLP-1 therapy with a qualified clinician.
REWIND trial · 9,901 participants · median 5.4 years · type 2 diabetes
Dulaglutide vs placebo - relative risk reduction across organ systems
Longer bar = greater risk reduction vs placebo →
Source: REWIND, Lancet (2019) and its exploratory kidney (Lancet, 2019) and cognitive (Lancet Neurology, 2020) analyses; NCT01394952, 9,901 participants, median 5.4 years. The cardiovascular endpoint was the trial's primary outcome; the cognitive and kidney results are exploratory (shown in a lighter tone) and need confirmation. Dulaglutide is approved for type 2 diabetes, not for cognitive or kidney indications. Educational summary of published research, not a treatment claim.
Related on Peak Human
Semaglutide
The once-weekly GLP-1 with greater weight loss - a common step up from dulaglutide.
Retatrutide
Investigational triple agonist - the most potent incretin in trials.
Metformin
Foundational metabolic-longevity agent, often paired with GLP-1s.
Longevity
Goal-based protocols where metabolic therapy supports healthspan.
Optimization at Peak Human
Physician-supervised, biomarker-tracked optimization programs.
Oral GLP-1
A GLP-1 option in the shop, via an independent third-party supplier.
Key references: Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND) - The Lancet (2019) · Effect of dulaglutide on cognitive impairment in type 2 diabetes (REWIND exploratory analysis) - The Lancet Neurology (2020) · Dulaglutide and renal outcomes in type 2 diabetes (REWIND exploratory analysis) - The Lancet (2019) · Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide (SURPASS-CVOT post hoc analysis) - JAMA Cardiology (2026)
Cost & Access
Cost Range
$$$
Accessibility
Availability varies by location
Sample member
Longevity Operator
One number for your longevity journey.
FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.
- Metabolic
- Hormonal
- Cardiovascular
- Brain / Cognitive
- Sleep
- Musculoskeletal
- Gut
- Immunity / Inflammation
